QTTB · Q32 Bio Inc
Price
Snapshot
50 fields · last close| Market Cap | $231.3M |
| P/E | 7.95 |
| Float | 24.00M |
| Beta | 0.50 |
| Volatility | 12.6% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Micro cap |
| Macro sensitivity | Low |
| Clavix score | 34.1 |
| Price | 7.42 |
| Change | −1.33% |
| Prev Close | 7.52 |
| Open | 8.01 |
| Day Low | 7.72 |
| Day High | 8.29 |
| Avg Vol | 1 |
| Avg $ Vol | $8.86M |
| 52W High | 23.57 |
| 52W Low | 1.91 |
| 52W Pos | 25.5% |
| From High | −68.52% |
| From Low | +289.50% |
| Max DD 1Y | −63.66% |
| Spread | 0.10% |
| Liquidity | Thin |
| SMA 20 | −15.74% |
| SMA 50 | −38.17% |
| SMA 200 | −17.14% |
| RSI (14) | 29.2 |
| Vol 30D | 69.4% |
| Vol 90D | 135.9% |
| 1Y Range | 2–24 |
| Daily bars | 535 |
| Perf Week | −3.96% |
| Perf Month | −29.23% |
| Perf Quarter | −48.37% |
| Perf Half Y | +35.84% |
| Perf Year | +100.78% |
| Perf YTD | +115.70% |
| Prev Day | −1.33% |
| Clavix | F |
| Debt / Eq | 2.29 |
| Curr Ratio | 4.85 |
| Int Cover | — |
| FCF Margin | −62.4% |
| Rev Growth | +155.8% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 33 / 35 |
Clavix risk grade
regraded every trading dayQTTB grades F, 34.1 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (10, weak). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 33 of 35 in Biotechnology by Clavix score.
How rough the ride is
| QTTB | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.50 | 0.50 |
| Volatilityannualized | 12.6% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −63.7% | — |
| Typical daily movemedian absolute daily change | 3.62% | — |
| Days beyond ±3%of the last 252 sessions | 150 (60%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| QTTB | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.50 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| QTTB | |
|---|---|
| 1 week | −4.0% |
| 1 month | −29.2% |
| Year to date | +115.7% |
| 1 year | +100.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| QTTB | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 10 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 3 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| QTTB | |
|---|---|
| Revenue growthyear over year | +155.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openQ32 Bio shared additional Part B results from its Phase 2a trial of bempikibart in severe alopecia areata (an autoimmune condition causing patchy hair loss), reporting a 35.3% average reduction in scalp hair loss severity (SALT score) at Week 36, plus full maintenance of hair regrowth through 16 weeks off the drug. The company said the data support moving into a registration-directed program in the first half of 2027.
Q32 Bio shared updated Phase 2a trial results for its alopecia areata drug bempikibart at a dermatology conference, showing a 35.3% average reduction in a standard severity-of-baldness score at Week 36 and suggesting the effect held up during a 16-week follow-up period after patients stopped taking the drug. The company said the results support moving into a larger, registration-focused study in the first half of 2027 and exploring less frequent dosing.
Q32 Bio reported 36-week results and 16-week off-drug findings from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in patients with severe or very severe alopecia areata, showing meaningful efficacy on primary and key secondary endpoints, durable response, and a safety profile consistent with prior studies.
Q32 Bio presented 36-week results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata at the EADV Congress, showing meaningful efficacy on primary endpoints and durable response after a 16-week off-drug period, with a safety profile consistent with prior studies.
Q32 Bio's drug bempikibart may offer lasting hair regrowth for alopecia areata, but this advantage still needs broader clinical validation. The article notes QTTB's improved financing gives short-term flexibility, with upcoming updates in 2H2026, 1H2027, and 2H2027 serving as the key tests of the bull case.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CELC | Celcuity Inc | C | $2.95B | — | 0.11 | Compare |
| PTCT | PTC Therapeutics Inc | B | $5.09B | 7.30 | 0.50 | Compare |
| ERAS | Erasca Inc | C | $5.20B | — | 0.67 | Compare |
| CGON | CG Oncology Inc | B- | $5.48B | — | 0.26 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $6.67B | — | 0.76 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.33B | — | 0.38 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.26B | — | 1.34 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.57B | 18.85 | 1.82 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.